Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models

INTRODUCTION: Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) that is approved for the use of EGFR-mutant non-small cell lung cancer (NSCLC) patients. In this study, we investigated the acquired resistance mechanisms in NSCLC patients and patient-derived preclinical models. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Sun Min, Yang, San-Duk, Lim, Sangbin, Heo, Seong Gu, Daniel, Stetson, Markovets, Aleksandra, Minoo, Rafati, Pyo, Kyoung-Ho, Yun, Mi Ran, Hong, Min Hee, Kim, Hye Ryun, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891830/
https://www.ncbi.nlm.nih.gov/pubmed/35251316
http://dx.doi.org/10.1177/17588359221079125

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891830/
https://www.ncbi.nlm.nih.gov/pubmed/35251316
http://dx.doi.org/10.1177/17588359221079125

Ejemplares similares